ArticlejLPHA : the official journal of the Louisiana Public Health Association2025
Research - Investigating Biomarkers Linking Tobacco Use with Cadiovascular Disease Occurrence.
Article in jLPHA : the official journal of the Louisiana Public Health Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Influence of cigarette smoking on cardio-inflammatory biomarkers among healthy individuals or cardiopulmonary disorder patients: systematic review and meta-analysis.International journal of cardiology. Cardiovascular risk and prevention · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background: Smoking has been associated with negative cardiovascular health outcomes. We analyzed data from The Population Assessment of Tobacco and Health (PATH) Study to investigate whether certain biomarkers collected were related to both cardiovascular disease (CVD) occurrence and cigarette or e-cigarette use. Methods: A total of 6,473 participants were grouped into cigarette users, e-cigarette users, and non-users. Among them, 6,020 (93%) developed CVD and 453 (7%) did not over PATH Study Waves 1 to 5. All participants were adults, had valid tobacco use and biomarker data, and no pre-existing CVD prior to Wave 1.We conducted mediation analysis using nonlinear multiple additive regression trees (MART) method to determine if there were biomarkers that mediated, or helped explain, the association between cigarette and e-cigarette use and cardiovascular disease occurrence. A total of 59 biomarkers were analyzed to determine their associations to cardiovascular disease. Results: There was a significant association (p< 0.001) between CVD and cigarette use, with cigarette users having 11% higher odds of CVD than non-users. Biomarkers soluble intercellular adhesion molecule-1 (sICAM-1) and high-sensitivity C-reactive protein (hsCRP) significantly mediated the relationship between cigarette use and CVD with relative indirect effect of 20.7% (95% CI: 4.5% - 45.6%) and 82.7% (95% CI: 51.2% - 100.0%), respectively. Although there were higher odds of CVD, no significant effect was found for exclusive e-cigarette users (p = 0.259). Conclusions: Inflammatory biomarkers sICAM-1 and hsCRP mediated the association between cigarette use and CVD, suggesting their potential as biomarkers for cardiovascular risk in smokers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.